Trends in Cardiovascular Medicine
Volume 16, Issue 1 , Pages 20-24 , January 2006

β1-Adrenergic Receptor Function, Autoimmunity, and Pathogenesis of Dilated Cardiomyopathy

  • Roland Jahns

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Roland Jahns, MD, Medizinische Klinik und Poliklinik I, University of Würzburg, Josef-Schneider-Strasse 2, D-97080 Würzburg, Germany. Tel.: +49-931-201-71190; fax: +49-931-201-70730.
    • ,
  • Valérie Boivin
    • ,
  • Martin J. Lohse

References 

  1. American Heart Association 2005. Heart Disease and Stroke Statistics—2005 Update. Dallas.
  2. Anderton SM. Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes, and possibilities. Immunology. 2001;104:367–376
  3. Bywater RP. Location and nature of the residues important for ligand recognition in G-protein coupled receptors. J Mol Recognit. 2005;18:60–72
  4. Caforio AL, Mahon NJ, Tona F, McKenna WJ. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail. 2002;4:411–417
  5. Centers for Disease Control and Prevention . Changes in mortality from heart failure, United States. JAMA. 1998;280:874–875
  6. Chiale PA, Ferrari I, Mahler E, et al. Differential profile and biochemical effects of antiautonomic membrane receptor antibodies in ventricular arrhythmias and sinus node dysfunction. Circulation. 2001;103:1765–1771
  7. Dohlman HG, Caron MG, De Blasi A, et al. Role of extracellular disulfide-bonded cysteines in the ligand binding function of the β2-adrenergic receptor. Biochemistry. 1990;29:2335–2342
  8. Elies R, Ferrari I, Wallukat G, et al. Structural and functional analysis of the B cell epitopes recognized by anti-receptor autoantibodies in patients with Chagas' disease. J Immunol. 1996;157:4203–4211
  9. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in β1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A. 1999;96:7059–7064
  10. Eriksson U, Ricci R, Hunziker L, et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med. 2003;9:1484–1490
  11. Ferrari I, Levin M, Wallukat G, et al. Molecular mimicry between the immunodominant ribosomal protein PO of Trypanosoma cruzi and a functional epitope on the human β1-adrenergic receptor. J Exp Med. 1995;182:59–65
  12. Freedman NJ, Lefkowitz RJ. Anti-β1-adrenergic receptor antibodies and heart failure: causation, not just correlation. J Clin Invest. 2004;113:1379–1382
  13. Frielle T, Collins S, Daniel KW, et al. Cloning of the cDNA for the human β1-adrenergic receptor. Proc Natl Acad Sci U S A. 1987;84:7920–7924
  14. Guillet JG, Hoebeke J, Lengagne R, et al. Haplotype specific homology scanning algorithm to predict T cell epitopes from protein sequences. J Mol Recognit. 1991;4:17–25
  15. Hershko AY, Naparstek Y. Removal of pathogenic autoantibodies by immunoadsorption. Ann N Y Acad Sci. 2005;1051:635–646
  16. Hoebeke J. Structural basis of autoimmunity against G protein-coupled membrane receptors. Int J Cardiol. 1996;54:103–111
  17. Hoffmann C, Leitz MR, Oberdorf-Maas S, et al. Comparative pharmacology of human β-adrenergic receptor subtypes: characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004;362:151–159
  18. Iwata M, Yoshikawa T, Baba A, et al. Autoantibodies against the second extracellular loop of β1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2001;37:418–424
  19. Jahns R, Siegmund C, Jahns V, et al. Probing human β1- and β2-adrenoceptors with domain-specific fusion protein antibodies. Eur J Pharmacol. 1996;316:111–121
  20. Jahns R, Boivin V, Siegmund C, et al. Activating β1-adrenoceptor antibodies are not associated with cardiomyopathies secondary to valvular or hypertensive heart disease. J Am Coll Cardiol. 1999;34:1545–1551
  21. Jahns R, Boivin V, Siegmund C, et al. Autoantibodies activating human β1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation. 1999;99:649–654
  22. Jahns R, Boivin V, Krapf T, et al. Modulation of β1-adrenoceptor activity by domain-specific antibodies and heart failure-associated autoantibodies. J Am Coll Cardiol. 2000;36:1280–1287
  23. Jahns R, Boivin V, Hein L, et al. Direct evidence for a β1-adrenergic receptor directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest. 2004;113:1419–1429
  24. Limas CJ. Cardiac autoantibodies in dilated cardiomyopathy. Circulation. 1997;95:1979–1980
  25. Limas CJ, Goldenberg IF, Limas C. Assessment of immune modulation of β-adrenergic pathways in human dilated cardiomyopathy: influence of methodologic factors. Am Heart J. 1992;123:967–970
  26. Limas CJ, Iakovis P, Anyfantakis A, et al. Familial clustering of autoimmune diseases in patients with dilated cardiomyopathy. Am J Cardiol. 2004;93:1189–1191
  27. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of β-adrenergic signaling in heart failure?. Circ Res. 2003;93:896–906
  28. Luppi P, Rudert WA, Zanone MM, et al. Idiopathic dilated cardiomyopathy. A superantigen-driven autoimmune disease. Circulation. 1998;98:777–785
  29. Magnusson Y, Hoyer S, Lengagne R, et al. Antigenic analysis of the second extracellular loop of the human β-adrenergic receptors. Clin Exp Immunol. 1989;78:42–48
  30. Magnusson Y, Wallukat G, Waagstein F, et al. Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the β1-adrenoceptor with positive chronotropic effect. Circulation. 1994;89:2760–2767
  31. Magnusson Y, Hjalmarson Å, Hoebeke J. β1-adrenoceptor autoimmunity in cardiomyopathy. Int J Cardiol. 1996;54:137–141
  32. Matsui S, Fu M, Katsuda S, et al. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol. 1997;29:641–655
  33. Mobini R, Staudt A, Felix SB, et al. Hemodynamic improvement and removal of autoantibodies against β1-adrenergic receptors by immunoadsorption therapy in dilated cardiomyopathy. J Autoimmun. 2003;20:345–350
  34. Morita H, Seidman J, Seidman CE. Genetic causes of human heart failure. J Clin Invest. 2005;115:518–526
  35. Neumann DA, Burek CL, Baughman KL, et al. Circulating heart-reactive antibodies in patients with myocarditis or cardiomyopathy. J Am Coll Cardiol. 1990;16:839–846
  36. Noda K, Saad Y, Graham RM, Karnik SS. The high affinity state of the β2-adrenergic receptor requires unique interaction between conserved and non-conserved extracellular loop cysteines. J Biol Chem. 1994;269:6743–6752
  37. Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003;9:1477–1483
  38. Omerovic E, Bollano E, Andersson B, et al. Induction of cardiomyopathy in severe combined immunodeficiency mice by transfer of lymphocytes from patients with idiopathic dilated cardiomyopathy. Autoimmunity. 2000;32:271–280
  39. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: a G-protein coupled receptor. Science. 2000;289:739–745
  40. Richardson P, McKenna W, Bristow M, et al. Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Circulation. 1996;93:841–842
  41. Rose NR. Infection, mimics, and autoimmune disease. J Clin Invest. 2001;107:943–944
  42. Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today. 1993;14:426–430
  43. Schultheiss HP, Bolte HD. Immunological analysis of autoantibodies against the adenine nucleotide translocator in dilated cardiomyopathy. J Mol Cell Cardiol. 1985;17:603–617
  44. Störk S, Boivin V, Horf R, et al. Activating autoantibodies against the human β1-adrenoceptor predict increased mortality in dilated cardiomyopathy. Circulation 110: abst. suppl. III, 555.
  45. Vilardaga JP, Steinmeyer R, Harms GS, Lohse MJ. Molecular basis of inverse agonism in a G protein-coupled receptor. Nature Chem Biol. 2005;1:25–28
  46. Wallukat G, Wollenberger A, Morwinski R, Pitschner HF. Anti-β1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol. 1995;27:397–406
  47. Wallukat G, Müller J, Hetzer R. Specific removal of β1-adrenergic antibodies directed against cardiac proteins from patients with idiopathic dilated cardiomyopathy. N Engl J Med. 2002;347:1806
  48. Wieland K, Zuurmond HM, Andexinger S, et al. Stereospecificity of agonist binding to β2-adrenergic receptors involves Asn-293. Proc Natl Acad Sci U S A. 1996;93:9276–9281
  49. Witebsky E, Rose NR, Terplan K, et al. Chronic thyroiditis and autoimmunization. JAMA. 1957;164:1439–1447
  50. Woodiwiss AJ, Tsotetsi OJ, Sprott S, et al. Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction. Circulation. 2001;103:155–160

PII: S1050-1738(05)00216-1

doi: 10.1016/j.tcm.2005.11.002

Trends in Cardiovascular Medicine
Volume 16, Issue 1 , Pages 20-24 , January 2006

Article Tools

* Image Usage & Resolution